RS
BIO icon

Ricky Sandler’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ricky Sandler’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-225,881
Closed -$85.6M – 64
2023
Q2 		$85.6M Buy
225,881
+57,866
+34% +$23.5M 1.12% 32
2023
Q1 		$80.5M Buy
+168,015
New +$78.7M 1.14% 38

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ricky Sandler's BIO Position: Q3 2023 in Review

Ricky Sandler sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 225,881 shares — an estimated $85.6M sold.

Ricky Sandler first reported a position in BIO in Q1 2023 and held it in 2 quarters. The position peaked at $85.6M in Q2 2023. 468 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • Ricky Sandler reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • Ricky Sandler sold 225,881 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $85.6M.
  • Ricky Sandler first reported a position in Bio-Rad Laboratories Class A in Q1 2023 and held it in 2 quarters.
  • Ricky Sandler's Bio-Rad Laboratories Class A position peaked at $85.6M in Q2 2023.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Eminence Capital's 13F filing for Q3 2023, filed 14 Nov 2023.